Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
Epistemonikos ID: 4b98a8b97234cdf3712f158d370a12d7d4c0e166
First added on: May 13, 2024